tbuckley/cabot-search huggingface dataset:
Original Article in J Thoracic Oncology Characterization, prognosis, and treatment of patients with locally advanced or metastatic thymic neuroendocrine tumor (Thy-NET): a retrospective study of the French GTE, ENDOCAN RENATEN and RYTHMIC networks
Authors: Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, Jose Carlos Benitez, Alice Durand, Helene Lasolle, Marine Perrier, Arnaud Jannin, Sandrine Laboureau, Maelle Lebras, Olivier Chabre, Sébastien Gaujoux, Lionel Groussin Rouiller, Olivia Hentic, Hélène Du Boullay, Magalie Haissaguerre, Hervé Kinn, Thierry Lecomte, Pierre Goudet, Nicolas Girard, Jean-Yves Scoazec, Benjamin Besse, Matthieu Faron, Eric Baudin
Journal: Journal of Thoracic Oncology (2025)
Bisphosphonate Bone Imaging Agent [68Ga]Ga-P15-041 for Evaluating Skeletal Metastases in Prostate Cancer
Authors: Jiarou Wang, Linlin Li, Tianrui Feng, Rongxi Wang, Jialin Xiang, Yaping Luo, Lin Zhu, Hank F. Kung, Weigang Yan, Zhaohui Zhu
Journal: Clinical Nuclear Medicine (2025)

Background: Accurate diagnosis of bone metastases in prostate cancer is essential for staging, prognosis, and treatment. Although PSMA PET/CT is highly effective, complementary imaging is needed to clarify indeterminate lesions. The novel bisphosphonate-based agent [ 68 Ga]Ga-P15-041 shows superior diagnostic accuracy over conventional SPECT imaging, indicating its potential as an auxiliary diagnostic tool. This study explores its role in detecting and assessing prostate cancer bone metastases. Patients and Methods: This prospective study enrolled 35 patients with prostate cancer and skeletal metastases, who underwent both [ 68 Ga]Ga-P15-041 and [ 68 Ga]Ga-PSMA-11 PET/CT within 1 week. Lesions detected by [ 68 Ga]Ga-PSMA-11 PET/CT were classified using Prostate-specific Membrane Antigen Reporting and Data System 2.0. Results: [ 68 Ga]Ga-P15-041 PET/CT detected more lesions than [ 68 Ga]Ga-PSMA-11 PET/CT (525 vs 509, P &lt; 0.001) and demonstrated significantly higher tracer uptake, with a mean SUV of 20.73 ± 14.67 compared with 11.13 ± 8.12 ( P &lt; 0.0001). It detected significantly more osteoblastic lesions (504 vs 391, P &lt; 0.0001). In addition, this study established the Reporting and Data System for [ 68 Ga]Ga-P15-041 (P15-041-RADS), which classifies prostate cancer bone metastases into 5 categories based on SUV max and morphologic changes. P15-041-RADS reclassified 85.71% of Prostate-specific Membrane Antigen Reporting and Data System category 3 lesions and 95.00% of 5T lesions into higher-confidence categories, offering improved diagnostic clarity. Limitations include small sample size and lack of pathologic gold standards. Conclusions: [ 68 Ga]Ga-P15-041 PET/CT is a promising and accessible bone imaging agent that could complement [ 68 Ga]Ga-PSMA-11 PET/CT in the diagnosis and classification of bone metastases in prostate cancer.
Brown Tumor Induced by Hyperparathyroidism Detected by 68Ga-FAPI-04 PET/CT
Authors: Zeyu Zhang, Yunshuo Zhang, Ye Peng, Changjing Zuo, Chao Cheng
Journal: Clinical Nuclear Medicine (2025)

A 50-year-old woman presented with persistent left hip pain. MRI suggested metastatic lesions or hematologic disease. Further evaluation with 68 Ga-FAPI-04 PET/CT revealed multiple skeletal lesions with radiotracer uptake and a non-avid low-density mass in the right parathyroid area. Elevated parathyroid hormone, hypercalcemia, and a 99m Tc-sestamibi-avid right parathyroid mass led to a diagnosis of right parathyroid adenoma causing secondary brown tumors. Surgical removal of the parathyroid mass confirmed the diagnosis, highlighting the efficacy of 68 Ga-FAPI-04 PET imaging in detecting brown tumors.
Diagnostic Accuracy of PSMA-targeted 18F-Florastamin PET/CT in Intermediate-risk Patients With Suspected Prostate Cancer
Authors: Jimin Yuei, Wonho Jung, Kyoung Sook Won, Teak-Jun Shin, Byoung Je Kim, Mi Sun Choe, Hye Ra Jung, Byung-Hoon Kim, Hae Won Kim
Journal: Clinical Nuclear Medicine (2025)

Purpose: This study aimed to evaluate the diagnostic accuracy of 18 F-Florastamin prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) in detecting intermediate-risk prostate cancer and compare its performance with multiparametric magnetic resonance imaging (mpMRI). Patients and Methods: Fifty-nine patients with suspected intermediate-risk prostate cancer (prostate-specific antigen: 3–20 ng/mL) were prospectively enrolled. All participants underwent examination with 18 F-Florastamin PET/CT and mpMRI, with imaging results assessed using the PSMA-Reporting and Data System and Prostate Imaging-Reporting and Data System Version 2.1 scoring systems, respectively. Prostate biopsy served as the reference standard. Diagnostic metrics, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the receiver operating characteristic curve (AUC), were calculated to compare the 2 modalities. Results: PSMA PET/CT demonstrated a sensitivity of 72.4%, specificity of 83.3%, and overall accuracy of 78%, with an AUC of 0.78 (95% CI: 0.67–0.89). Contrastingly, mpMRI showed a higher sensitivity (89.7%) but lower specificity (66.7%), achieving the same overall accuracy of 78% and an AUC of 0.78 (95% CI: 0.68–0.88). No statistically significant difference in AUC was observed between the 2 modalities ( P =0.967). While PSMA PET/CT offered higher specificity and PPV, reducing false-positive results, mpMRI excelled in sensitivity and NPV, minimizing false negatives. Conclusions: 18 F-Florastamin PSMA PET/CT demonstrated comparable diagnostic accuracy to mpMRI, with the added benefit of higher specificity. These findings suggest that PSMA PET/CT could complement mpMRI in the diagnostic evaluation of intermediate-risk prostate cancer, enhancing patient stratification and aiding clinical decision-making.
Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma
Authors: Jingjing Zhang, Deling Li, Mengqi Shi, Vivianne Jakobsson, Wang Jia, Harshad R. Kulkarni, Christiane Schuchardt, Richard P. Baum
Journal: Clinical Nuclear Medicine (2025)

Background: Peptide receptor radionuclide therapy (PRRT) offers a promising treatment option by targeting the high density of somatostatin receptors overexpressed in meningiomas. The objective of this study aimed to evaluate the long-term outcome of PRRT in patients with refractory meningioma. Patients and Methods: Eighteen patients with refractory meningioma, presenting with progression or recurrence despite surgery or radiotherapy or having inoperable tumors and lack of other therapeutic options, received PRRT with 177 Lu-labeled or 90 Y-labeled somatostatin analogs (DOTATATE, DOTATOC, or HA-DOTATATE) between January 2004 and December 2019. Treatment response was evaluated according to the Response Assessment in Neuro-Oncology, Response Evaluation Criteria in Solid Tumors, and molecular imaging criteria. Results: Most patients received 2 cycles of PRRT, and up to 4 cycles were applied. The mean total administered activity was 12.7 GBq (range: 8.5–28.5 GBq). Of 14 patients monitored after 2 cycles of PRRT, disease control was reached in 12 (85.7%) patients. The median progression-free survival was 32.3 months, and the median OS has yet to be reached with a median follow-up of 67.1 months. All patients tolerated the therapy without any serious acute adverse effects. No Common Terminology Criteria for Adverse Event grades 2–4 anemia, leukopenia, or thrombocytopenia toxicities were observed during or after PRRT. No renal toxicity, hepatotoxicity, or late radiation adverse effects were reported during long-term follow-up. Conclusions: PRRT showed promising outcomes in patients with refractory meningiomas, with high disease control and encouraging progression-free survival and OS, and therefore appears to be a favorable therapeutic option. With long-term follow-up, PRRT demonstrated a favorable safety profile, resulting in very few side effects in this cohort of patients with meningioma.
Bio‐Functionalized MXenes: Synthesis and Versatile Applications
Authors: Hossein Vojoudi, Masoud Soroush
Journal: Advanced Healthcare Materials (2025)

Abstract MXenes exhibit remarkable properties, including high electrical conductivity, tunable surface chemistry, outstanding mechanical strength, and notable hydrophilicity. Recent advancements in bio‐functionalization have further enhanced these intrinsic characteristics, unlocking unprecedented opportunities for MXenes across a wide spectrum of applications in both biomedical and environmental domains. This review provides an in‐depth analysis of the synthesis strategies and functionalization techniques that improve MXenes' biocompatibility and expand their potential uses in cutting‐edge applications, including implantable and wearable devices, drug delivery systems, cancer therapies, tissue engineering, and advanced sensing technologies. Moreover, the review explores the utility of bio‐functionalized MXenes in areas such as corrosion protection, water purification, and food safety sensors, underscoring their versatility in addressing urgent global challenges. By conducting a critical evaluation of current research, this review not only highlights the immense potential of bio‐functionalized MXenes but also identifies pivotal gaps in the literature, offering clear pathways for future exploration and innovation in this rapidly evolving field.
Physical Encapsulation and Chemotherapy: A Synergistic Hydrogel Strategy for Tumor Suppression
Authors: Yajie Gong, Weiguang Yuan, Siyu Liu, Mengru Jin, Siwei Li, Lingling Tao, Yijun Chu, Hui Li, Yuanyuan Yu, Xi Chen, Youxue Zhang, Da Pang, Xianyu Zhang
Journal: Advanced Healthcare Materials (2025)

Abstract Conventional chemotherapy remains a fundamental strategy for cancer treatment but is often limited by systemic toxicity. To address this challenge, Mix Gel is developed as a hybrid hydrogel combining the biocompatibility of decellularized omentum hydrogel and the mechanical stability of sodium alginate. Peritumoral injection of Mix Gel effectively achieves tumor encapsulation and growth inhibition. To enhance therapeutic efficacy, doxorubicin is incorporated, forming DOX‐Mix Gel, which synergistically improves antitumor outcomes through physical encapsulation and sustained drug release. In vivo, DOX‐Mix Gel significantly inhibits tumor proliferation, induces apoptosis, disrupts blood supply, and triggers metabolic stress, resulting in marked tumor suppression. Mix Gel provides a scalable, minimally invasive, and clinically promising strategy for solid tumor therapy.
Corticosteroids for adult patients hospitalised with non-viral community-acquired pneumonia: a systematic review and meta-analysis
Authors: Tyler Pitre, Ellen Pauley, Dipayan Chaudhuri, Rohit Saha, Kristina E Rudd, Jesús Villar, Lindsay R Berry, Elizabeth Lorenzi, Thomas Hills, Alistair Nichol, David A Harrison, Simon Finfer, Jeremy Cohen, John Myburgh, Naomi Hammond, Domingo Martínez, Cristina Fernández, David Antcliffe, Anthony Gordon, André Scherag, Holger Bogatsch, Frank M Brunkhorst, Balasubramanian Venkatesh, Djillali Annane, Danny McAuley, Derek C Angus, Bram Rochwerg, Manu Shankar-Hari
Journal: Intensive Care Medicine (2025)
Atrial fibrillation in critical illness: state of the art
Authors: Stephanie Sibley, Jonathan Bedford, Mik Wetterslev, Brian Johnston, Tessa Garside, Salmaan Kanji, Tony Whitehouse, Ingeborg Welters, Marlies Ostermann, Martin Balik, Daniel Lancini, Blossom Dharmaraj, Emelia J Benjamin, Allan J Walkey, Brian H Cuthbertson
Journal: Intensive Care Medicine (2025)
Maintaining ventilation with very low tidal volume and positive-end expiratory pressure versus no ventilation during cardiopulmonary bypass for cardiac surgery in adults: a randomized clinical trial
Authors: Jean-Marc Tadié, Alexandre Ouattara, Bruno Laviolle, Mathieu Lesouhaitier, Maxime Esvan, Chloé Rousseau, Murielle Grégoire, Baptiste Gaudriot, Nicolas Nesseler, François Labaste, Pascale Sanchez, Bertrand Marcheix, Antoine Beurton, Pauline Dureau, Pierre Demondion, Olivier Fouquet, Emmanuel Rineau, Julien Amour, Jean-Philippe Verhoye, Alain Mercat, Nicolas Terzi, Karin Tarte, Adrien Bouglé, Erwan Flecher
Journal: Intensive Care Medicine (2025)

Cardiopulmonary bypass (CPB) during cardiac surgery mechanically circulates and oxygenates the blood, bypassing the heart and lungs. Despite limited evidence, maintaining mechanical ventilation (MV) during CPB is recommended, as ventilator strategies during surgery may reduce the occurrence of postoperative infections. We aimed to determine whether maintaining MV for cardiac surgery would decrease postoperative infections compared with stopping MV during CPB. We conducted a multicenter, single-blind, randomized trial among adult patients undergoing scheduled cardiac surgery with CPB in six hospitals in France. During CPB, the tracheal tube was disconnected from the ventilator in the control group (MV- group). In the MV + group, ventilation was maintained during CPB with very low tidal volume ventilation, using a tidal volume of 2.5 mL/kg of predicted body weight, with 5-7 cmH2O positive end expiratory pressure. The primary outcome was the occurrence of all types of postoperative infections within the first 28 days after surgery. There were six secondary evaluation criteria including the number of days of exposure to antibiotics. A total of 1362 patients were enrolled in the study. Postoperative infection occurred in 74 out of 680 patients (10.9%) in the MV- group, compared to 68 out of 682 patients (10.0%) in the MV + group (relative risk, 0.92; 95% confidence interval [CI] 0.67-1.25; p = 0.58). Antibiotic use was higher in the MV + group than in the MV- group (incidence risk ratio, 1.08; 95% CI 1.02-1.15; p = 0.02). There were no significant differences between the groups for all other secondary outcomes or for the incidence of adverse events. Maintaining very low tidal volume ventilation with positive end-expiratory pressure during CPB did not reduce postoperative infections at 28 days compared to when mechanical ventilation was stopped during CPB. An unexpectedly higher use of antibiotics was observed when ventilation was maintained. ClinicalTrials.gov (NCT03372174).
Enhancer-Associated LncRNA-ITGA2 Promotes Vascular Remodeling Through ITGA2
Authors: Xian Guo, Pan Hou, Sha Zhang, Qiang Xu, Mingyao Zhou, Wendong Tang, Faguang Jin, Bili Zhang, Zhifu Guo, Xianxian Zhao, Yue Wang, Junfeng Jiang, Pan Li
Journal: Circulation Research (2025)

BACKGROUND: The proliferation and migration of vascular smooth muscle cells (VSMCs) significantly contribute to vascular remodeling. Recent studies have suggested that enhancer-associated long noncoding RNAs (elncRNAs) play crucial roles in regulating gene expression and cell fate. However, the specific elncRNAs implicated in VSMC dysfunction and their regulatory mechanisms remain poorly understood. METHODS AND RESULTS: This study used multiomics profiling, including CUT&amp;Tag, promoter capture high-throughput chromosome conformation capture, and microarray analysis, to identify long noncoding RNA (LncRNA)-ITGA2 (integrin α2) as a novel elncRNA highly expressed in PDGF (platelet-derived growth factor)–induced proliferative human VSMCs. Notably, LncRNA-ITGA2 was significantly elevated in the coronary atherosclerotic tissues of patients with coronary artery disease compared with those of control subjects. Gain-of-function and loss-of-function studies suggested that LncRNA-ITGA2 markedly enhanced PDGF-induced VSMC proliferation and migration. In vivo, the overexpression of LncRNA-ITGA2 promoted neointimal hyperplasia in a mouse carotid artery injury model, indicating its partial functional conservation. Using RNA sequencing and CRISPR-Cas9 gene editing technology, we identified ITGA2 as a downstream target of LncRNA-ITGA2. Mechanistically, promoter capture high-throughput chromosome conformation capture detected promoter-enhancer interactions at the ITGA2 locus after PDGF-BB (platelet-derived growth factor BB) treatment. Chromatin immunoprecipitation sequencing and chromatin isolation by RNA purification–quantitative polymerase chain reaction demonstrated that LncRNA-ITGA2 directly bound to the enhancer-ITGA2 and increased histone H3 on lysine 27 acetylation in both the enhancer-ITGA2 and the promoter-ITGA2. In addition, chromatin isolation by RNA purification–mass spectrometry and RNA immunoprecipitation revealed that LncRNA-ITGA2 interacted with the DNA-binding protein NONO (nonpou domain containing octamer–binding protein), which also bound to the ITGA2 promoter, as confirmed by chromatin immunoprecipitation–quantitative polymerase chain reaction. Ultimately, the use of knockout cell lines for NONO, LncRNA-ITGA2, and its promoter validated the proposed regulatory mechanism. CONCLUSIONS: This study identifies a novel mechanism by which elncRNA (LncRNA-ITGA2), in a NONO-dependent manner, mediates interactions between Enhancer-ITGA2 and Promoter-ITGA2, resulting in increased ITGA2 expression and subsequently promoting VSMC proliferation and migration. These findings highlight LncRNA-ITGA2 as an attractive diagnostic and therapeutic target for human proliferative vascular diseases.
Democratizing dementia research through global online conferences
Authors: Sara E Zsadanyi, Elizabeth Addison, Suvarna Alladi, Shea J Andrews, Keerthana Bs, Giovanna Carello-Collar, Olga Dubljević, Alexander J Ehrenberg, Francesca R Farina, Lea T Grinberg, Agustin Ibáñez, Adam Martersteck, Abebaw Nigussie, Emily J Rogalski, Kaitlin Seibert, Elka Stefanova, Kristine Yaffe, Yared Z Zewde, Eduardo R Zimmer, Igor C Fontana, Claire E Sexton
Journal: Nature Neuroscience (2025)
Quasi-spatial single-cell transcriptome based on physical tissue properties defines early aging associated niche in liver
Authors: Kwon Yong Tak, Juyeon Kim, Myungsun Park, Wooseok Kim, Seoyeong Lee, Narae Park, Min Jeong Kim, Ju-Bin Kang, Yongjun Koh, Hae Young Yang, Min Kyu Yum, Injune Kim, Yong Ryoul Yang, Won-Il Jeong, Jinsung Yang, Cheolju Lee, Chuna Kim, Jong-Eun Park
Journal: Nature Aging (2025)
Near-complete Middle Eastern genomes refine autozygosity and enhance disease-causing and population-specific variant discovery
Authors: Mohammadmersad Ghorbani, Shabir Moosa, Zenab Siddig, Radi Farhad, Haroon Naeem, William T Harvey, Francesco Kumara Mastrorosa, Katherine M Munson, Rozaimi Mohamad Razali, Elbay Aliyev, Ilhame Diboun, Rawan Abouelhassan, Melissa Tauro, Sondoss Hassan, Rebecca Mathew, Muna Al Hashmi, Lisa S Mathew, Kun Wang, Abdul Rahman Salhab, Fazulur Rehaman Vempalli, Ahmed El Khouly, Iman Alazwani, Sara Tomei, Khalid A Fakhro, Alia Satti, Ruba Benini, Arang Rhie, Evan E Eichler, Younes Mokrab
Journal: Nature Genetics (2025)

Abstract Advances in long-read sequencing have enabled routine complete assembly of human genomes, but much remains to be done to represent broader populations and show impact on disease-gene discovery. Here, we report highly accurate, near-complete and phased genomes from six Middle Eastern (ME) family trios ( n = 18) with neurodevelopmental conditions, representing ancestries from Sudan, Jordan, Syria, Qatar and Afghanistan. These genomes revealed 42.2 Mb of new sequence (13.8% impacting known genes), 75 new HLA/KIR alleles and strong signals of inbreeding, with ROH covering up to one-third of chromosomes 6 and 12 in one individual. Using assembly-based variant calling, we identified 23 de novo and recessive variants as strong candidates for causing previously unresolved symptoms in the probands. The ME genomes revealed unique variation relative to existing references, showing enhanced mappability and variant calling. These results underscore the value of de novo assembly for disease variant discovery and the need for sampled ME-specific references to better characterize population-relevant variation.
Inhibition of Adipose Tissue Lipolysis Treats Obesity-Related HFpEF
Authors: Alina Stockner, Maria Degli Innocenti, Daksh Verma, Sophie Schmid, Alexander Fuerlinger, Anila Varghese, Andreas Zirlik, Renate Schreiber, Rolf Breinbauer, Mahmoud Abdellatif, Simon Sedej
Journal: Circulation Research (2025)
Neonatal microbiota colonization primes maturation of goblet cell–mediated protection in the pre-weaning colon
Authors: Åsa Johansson, Mahadevan Venkita Subramani, Bahtiyar Yilmaz, Elisabeth E.L. Nyström, Elena Layunta, Liisa Arike, Felix Sommer, Philip Rosenstiel, Lars Vereecke, Louise Mannerås-Holm, Andy Wullaert, Thaher Pelaseyed, Malin E.V. Johansson, George M.H. Birchenough
Journal: The Journal of Experimental Medicine (2025)

Regulated host–microbe interactions are a critical aspect of lifelong health. Colonic goblet cells protect from microorganisms via the generation of a mucus barrier structure. Bacteria-sensing sentinel goblet cells provide secondary protection by orchestrating mucus secretion when microbes breach the mucus barrier. Mucus deficiencies in germ-free mice implicate a role for the microbiota in programming barrier generation, but its natural ontogeny remains undefined. We now investigate the mucus barrier and sentinel goblet cell development in relation to postnatal colonization. Combined in vivo and ex vivo analyses demonstrate rapid and sequential microbiota-dependent development of these primary and secondary goblet cell protective functions, with dynamic changes in mucus processing dependent on innate immune signaling via MyD88 and development of functional sentinel goblet cells dependent on the NADPH/dual oxidase family member Duox2. Our findings identify new mechanisms of microbiota–goblet cell regulatory interaction and highlight the critical importance of the pre-weaning period for the normal development of protective systems that are key legislators of host–microbiota interaction.
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial
Authors: Piet Ost, Shankar Siva, Sigmund Brabrand, Piet Dirix, Nick Liefhooghe, François-Xavier Otte, Alfonso Gomez-Iturriaga, Wouter Everaerts, Mohamed Shelan, Antonio Conde-Moreno, Fernando López Campos, Alexandros Papachristofilou, Matthias Guckenberger, Marta Scorsetti, Almudena Zapatero, Ana-Elena Villafranca Iturre, Clara Eito, Felipe Couñago, Paolo Muto, Wim Duthoy, Nicolas Mach, Valérie Fonteyne, Daniel Moon, Kristian Thon, Carole Mercier, Vérane Achard, Karin Stellamans, Els Goetghebeur, Dries Reynders, Thomas Zilli
Journal: The Lancet Oncology (2025)